These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy. Stevens DL; Lee MR; Padua Y Pharmacotherapy; 2008 Mar; 28(3):403-5. PubMed ID: 18294120 [TBL] [Abstract][Full Text] [Related]
3. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]. Khaldi S; Kornreich C; Choubani Z; Gourevitch R Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460 [TBL] [Abstract][Full Text] [Related]
4. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. Musselman ME; Browning LA; Parker D; Saely S Ann Pharmacother; 2011 Nov; 45(11):e61. PubMed ID: 21972252 [TBL] [Abstract][Full Text] [Related]
5. Olanzapine-associated neuroleptic malignant syndrome. Norgard NB; Stark JE Pharmacotherapy; 2006 Aug; 26(8):1180-2. PubMed ID: 16863495 [TBL] [Abstract][Full Text] [Related]
6. Atypical neuroleptic malignant syndrome - A case report. Vellekkatt F; Kuppili PP; Bharadwaj B; Menon V Asian J Psychiatr; 2019 Jun; 43():7-8. PubMed ID: 31071486 [TBL] [Abstract][Full Text] [Related]
7. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine. Mishra B; Mishra B; Sahoo S; Arora M; Khess CR Indian J Med Sci; 2007 Oct; 61(10):570-3. PubMed ID: 17932448 [TBL] [Abstract][Full Text] [Related]
9. Olanzapine-induced Neuroleptic Malignant Syndrome. Saha PK; Chakraborty A; Layek AK; Chakraborty A Indian J Psychol Med; 2017; 39(3):364-365. PubMed ID: 28615778 [TBL] [Abstract][Full Text] [Related]
10. Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report. Chang CK; Payus AO; Noh MM; Lansing MG; Sumpat D; Lu SJA; Yew BT J Med Case Rep; 2022 Oct; 16(1):366. PubMed ID: 36203196 [TBL] [Abstract][Full Text] [Related]
11. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Yacoub A; Francis A Neuropsychiatr Dis Treat; 2006 Jun; 2(2):235-40. PubMed ID: 19412469 [TBL] [Abstract][Full Text] [Related]
13. Neuroleptic malignant syndrome due to olanzapine. Hall KL; Taylor WH; Ware MR Psychopharmacol Bull; 2001; 35(3):49-54. PubMed ID: 12397878 [TBL] [Abstract][Full Text] [Related]
15. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. Srivastava A; Borkar HA; Chandak S Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992 [TBL] [Abstract][Full Text] [Related]
16. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. Abu-Kishk I; Toledano M; Reis A; Daniel D; Berkovitch M J Toxicol Clin Toxicol; 2004; 42(6):921-5. PubMed ID: 15533033 [TBL] [Abstract][Full Text] [Related]
17. Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene. Kouparanis A; Bozikas A; Spilioti M; Tziomalos K Brain Inj; 2015; 29(5):658-60. PubMed ID: 25625410 [TBL] [Abstract][Full Text] [Related]
20. [Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine]. Hanel RA; Sandmann MC; Kranich M; De Bittencourt PR Arq Neuropsiquiatr; 1998 Dec; 56(4):833-7. PubMed ID: 10029891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]